| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Executive Chairman | Chief Executive Officer | Director +1 more
8 companies
Joshua Silverman is Director at PTPI, with reported holdings spanning 8 companies. Joshua Silverman's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $994K at current prices.
Our model assigns Joshua Silverman a middling insider score of 62/100, based on 13 past trades. Over a 12-month horizon, 70.0% of those trades were profitable, with an average 12-month return of +30.1%.
Joshua Silverman's largest disclosed position is in FABC as Chief Executive Officer, worth about $467K.
Joshua Silverman has 64 Form 4 filings on record from June 2016 to September 2026, across 9 companies: Chief Executive Officer at Fabric.AI (FABC), 2026; Executive Chairman at Q/C Technologies (QCLS), 2019–2026; Director at Petros Pharmaceuticals (PTPI), 2020–2026, and 6 more.
The 105 reported transactions were 35 option or other derivative awards, 24 stock awards, 16 other transactions and 10 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 4 purchases worth about $305K and 6 sales worth about $260K.
The largest open-market purchase was 15,000 shares of QCLS at an average $6.89 on November 26, 2021, about $103K. Twelve months later QCLS was down 71%.
The largest open-market sale was 39,008 shares of SBLX at an average $5.17 on June 4, 2021, about $202K. Twelve months later SBLX was down 80%.
Both sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 7, 2026 | PMCB Pharmacyte Biotech, Inc. | CEO and President | Buy | 100,000 | $0.80 | $80,476.00 | +31.6% | -17.9% | - | |
| Aug 1, 2023 | SBLX Stablex Technologies, Inc. | Director | Sell10b5-1 | 12,740 | $0.82 | $10,385.65 | -3.1% | -76.5% | -89.0% | |
| May 3, 2023 | SBLX Stablex Technologies, Inc. | Director | Sell10b5-1 | 11,927 | $0.49 | $5,813.22 | -2.8% | +68.0% | -70.2% | |
| Jan 30, 2023 | SBLX Stablex Technologies, Inc. | Director | Sell | 7,171 | $0.71 | $5,107.90 | -3.1% | -24.7% | -68.1% | |
| Dec 16, 2022 | TAOX Tao Synergies Inc. | Director | Sell | 19,012 | $1.17 | $22,280.16 | -33.2% | -29.9% | -77.2% | |
| Nov 1, 2022 | SBLX Stablex Technologies, Inc. | Director | Sell | 20,026 | $0.74 | $14,785.61 | -8.0% | +16.6% | -68.4% | |
| Nov 26, 2021 | QCLS Q/c Technologies, Inc. | Director | Buy | 15,000 | $6.89 | $103,357.66 | +20.3% | -48.6% | -70.7% | |
| Jun 14, 2021 | TAOX Tao Synergies Inc. | Director | Buy | 10,000 | $8.30 | $83,000.00 | +200.0% | -16.9% | -38.3% | |
| Jun 4, 2021 | SBLX Stablex Technologies, Inc. | - | Sell | 39,008 | $5.17 | $201,686.96 | -22.4% | -20.0% | -80.0% | |
| Jun 26, 2018 | SBLX Stablex Technologies, Inc. | Director | Buy | 30,000 | $1.26 | $37,904.68 | +587.2% | - | - |